Cargando…

Cariprazine add-on for resistant bipolar depression: preliminary results from an italian real-world experience

INTRODUCTION: Depressive episodes represent the most frequent mood alteration in bipolar disorder (BD). Persistent depressive episodes and subsyndromic depressive symptoms often lead to poor quality of life and increase suicide risk. Recent studies have also shown that BD patients with a history of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martiadis, V., Pessina, E., Martini, A., Raffone, F., De Berardis, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595811/ http://dx.doi.org/10.1192/j.eurpsy.2023.623

Ejemplares similares

LAI-2 adjunctive treatment for type I Bipolar patients with comorbid Obsessive Compulsive Disorder: preliminary data from a real-world multi-centric Italian clinical experience
por: Martiadis, V., et al.
Publicado: (2023)

Cariprazine’s efficacy in treating depressive symptoms – pooled data from schizophrenia, bipolar depression and major depression trials
por: McIntyre, R. S., et al.
Publicado: (2023)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
por: Berardis, Domenico De, et al.
Publicado: (2021)

Clinical effects of Cariprazine and their relationship with polymorphisms of dopamine and serotonin receptors: preliminary results from a prospective study on schizophrenia and bipolar disorder
por: De Pieri, M., et al.
Publicado: (2022)

Intranasal esketamine + Intensive CBT: a 12 months follow-up of two complicated cases of Treatment Resistant Depression at high suicidal risk
por: Martiadis, V., et al.
Publicado: (2023)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
por: Martiadis, V., et al.
Publicado: (2022)

Brexpiprazole augmentation in a clozapine-resistant young schizophrenic patient: a successful case report.
por: Martiadis, V., et al.
Publicado: (2023)

Metacognition in schizophrenia: A practical overview of psychometric metacognition assessment tools for researchers and clinicians
por: Martiadis, Vassilis, et al.
Publicado: (2023)

Cariprazine in Three Special Different Areas: A Real-World Experience
por: Gesi, Camilla, et al.
Publicado: (2021)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes, Jose M, et al.
Publicado: (2021)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence
por: Rancans, E., et al.
Publicado: (2023)

Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy
por: Tarzian, Martin, et al.
Publicado: (2023)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

Metacognition, emotional dysregulation, psychosocial functioning and subjective well-being after 6 months of CBT treatment in pharmacologically stabilized schizophrenic patients
por: Raffone, F., et al.
Publicado: (2023)

Benzodiazepine use during cariprazine treatment in acute schizophrenia
por: Correll, C., et al.
Publicado: (2022)

New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine
por: Werner, Felix-Martin, et al.
Publicado: (2015)

Depressive and Anxious Temperaments as Predictors of Late Onset Bipolar Disorder? Preliminary Results of a “Real World” Exploratory Study
por: Orsolini, Laura, et al.
Publicado: (2022)

Efficacy and safety of cariprazine in bipolar I depression: A double‐blind, placebo‐controlled phase 3 study
por: Earley, Willie R., et al.
Publicado: (2019)

Cariprazine pharmacokinetics
Publicado: (2022)

Effectiveness of vortioxetine in real-world clinical practice: Italian cohort results from the global RELIEVE study
por: De Filippis, S., et al.
Publicado: (2022)

Italian validation of the Guilt And Shame Proneness Scale: preliminary results
por: Faccini, F., et al.
Publicado: (2022)

Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data
por: Stahl, Stephen M., et al.
Publicado: (2020)

Combined use of clozapine and cariprazine in treatment-resistant schizophrenia, is it a good choice?
por: Darriba, H. Becerra
Publicado: (2021)

Cariprazine treatment in patients with psychosis related to Parkinson’s Disease: a case report.
por: Martín De Argila Lorente, M., et al.
Publicado: (2023)

Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel
por: Fagiolini, Andrea, et al.
Publicado: (2020)

Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania
por: Periclou, Antonia, et al.
Publicado: (2019)

Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
por: Csehi, Réka, et al.
Publicado: (2022)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial
por: Yatham, Lakshmi N., et al.
Publicado: (2020)

Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
por: Tohen, Mauricio
Publicado: (2021)

Antenatal depression, obstetric outcomes, and post-partum depression: results from a longitudinal, real-world study
por: Di Vincenzo, M., et al.
Publicado: (2023)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies
por: McIntyre, Roger S., et al.
Publicado: (2020)

Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies
por: Patel, Mehul, et al.
Publicado: (2020)

Use of cariprazine as an impulsivity regulator in an adolescent with non suicidal self-injury and suicidal attempts. Case report
por: Del Sol Calderon, P., et al.
Publicado: (2023)

Psychosocial consequences of the COVID-19 social isolation in the italian general population: Preliminary results
por: Ciaramella, A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_57d9445d7jo0b67cr2rkm52osn